KPL-301 for Subjects With Giant Cell Arteritis
Completed · Phase 2 · Has a placebo group
Conditions studied: Giant Cell Arteritis
In brief
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).
Key facts
- Study ID
- NCT03827018
- Run by
- Kiniksa Pharmaceuticals, Ltd.
- People needed
- 70
- Starts
- 2018-09-20
- Expected to finish
- 2020-11-25
- Last updated by the study team
- 2023-10-23
Who can join
Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Site 1703 — Sarasota, Florida, United States
- Site 1708 — Tampa, Florida, United States
- Site 1706 — Atlanta, Georgia, United States
- Site 1701 — Boston, Massachusetts, United States
- Site 1707 — Lansing, Michigan, United States
- Site 1704 — Saint Clair Shores, Michigan, United States
- Site 1702 — Rochester, Minnesota, United States
- Site 1705 — New York, New York, United States
- Site 2102 — Kogarah, Australia
- Site 2105 — Nedlands, Australia
- Site 2106 — Parkville, Australia
- Site 2101 — Victoria Park, Australia
- Site 2104 — Woodville South, Australia
- Site 2204 — Brussels, Belgium
- Site 2202 — Leuven, Belgium
- Site 2201 — Liège, Belgium
- Site 2203 — Yvoir, Belgium
- Site 2303 — Zagreb, Croatia
- Site 2401 — Tallinn, Estonia
- Site 2402 — Tartu, Estonia
- Site 2502 — Tübingen, Baden-Wurttemberg, Germany
- Site 2504 — Erlangen, Bavaria, Germany
- Site 2507 — Freiburg im Breisgau, Germany
- Site 2506 — Hamburg, Germany
- Site 2503 — Hanover, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.